Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow RELMADA THERAPEUTICS, INC.

Get SEC filing alerts via email and in your feed for RELMADA THERAPEUTICS, INC.

RLMD

RELMADA THERAPEUTICS, INC.

About RELMADA THERAPEUTICS, INC.

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing novel drugs for neurological, psychiatric, and cancer-related conditions. Its pipeline includes candidates targeting depression, Tourette Syndrome, bladder cancer, and neurosteroid-related disorders. The company leverages extensive intellectual property, strategic licensing, and acquisitions to address high unmet medical needs, aiming for long-term growth through innovative, differentiated therapies in large markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from RELMADA THERAPEUTICS, INC.

1
1
RELMADA THERAPEUTICS, INC. Relmada Therapeutics Reports $19.05 Million Net Loss and Significant Cash Position Growth

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
RELMADA THERAPEUTICS, INC. Relmada Therapeutics Reports $57.4 Million Net Loss for Fiscal Year 2025, Focuses on New Clinical Candidates

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
RELMADA THERAPEUTICS, INC. Relmada Therapeutics Reports $10.1 Million Net Loss in Q3 2025, Focuses on NDV-01 Development

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
RELMADA THERAPEUTICS, INC. Relmada Therapeutics Reports Decreased Net Loss and Strategic Pipeline Changes in Latest 10-Q

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
RELMADA THERAPEUTICS, INC. Relmada Therapeutics Reports $17.6 Million Net Loss, Acquires Sepranolone and Licenses NDV-01

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
RELMADA THERAPEUTICS, INC. Relmada Therapeutics Reports Decreased Net Loss and Strategic Shift in Drug Development

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
RELMADA THERAPEUTICS, INC. Relmada Therapeutics Reports Significant Financial Decline, Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments